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Abstract
Background: The tuberculin skin test (TST) is used to test for latent tuberculosis (TB) infection and support the
diagnosis of active TB. However, little is known about the relationship between the TST result and the clinical
presentation of TB disease.
Methods: We analyzed US TB surveillance data, 1993–2010, and used multinomial logistic regression to calculate
the association between TST result (0–4 mm [negative], 5–9 mm, 10–14 mm, and ≥ 15 mm) and clinical
presentation of disease (miliary, combined pulmonary and extrapulmonary, extrapulmonary only, non-cavitary
pulmonary, and cavitary pulmonary). For persons with pulmonary disease, multivariate logistic regression was used
to calculate the odds of having acid-fast bacilli (AFB) positive sputum.
Results: There were 64,238 persons with culture-confirmed TB included in the analysis, which was stratified by HIV
status and birthplace (US- vs. foreign-born). Persons with a TST ≥ 15 mm were less likely to have miliary or
combined pulmonary and extrapulmonary disease, but more likely to have cavitary pulmonary disease than non-
cavitary pulmonary disease. Persons with non-cavitary pulmonary disease with a negative TST were significantly
more likely to have AFB positive sputum.
Conclusions: Clinical presentation of TB disease differed according to TST result and persons with a negative TST
were more likely to have disseminated disease (i.e., miliary or combined pulmonary and extrapulmonary). Further
study of the TST result may improve our understanding of the host-pathogen relationship in TB disease.
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Background
The tuberculin skin test (TST) is primarily used to iden-
tify latent tuberculosis (TB) infection in persons who
may be at risk of progression to active disease and to
support the diagnosis of active TB disease [1,2]. A posi-
tive TST result, consisting of measurable skin induration
after the injection of tuberculin purified protein deriva-
tive, is part of a delayed-type hypersensitivity response
of host immune system memory T cells sensitized by
prior mycobacterial exposure [3]. However, the TST is
an imperfect marker of TB infection and previous
reports indicate that 10–25% of persons with active TB
disease have a negative TST result [1,4,5].
At the same time, it is well recognized that the host
immune system is an important determinant of the clin-
ical presentation of active TB disease, and patients with
an immature or suppressed immune system often have
faster disease progression and more disseminated disease
[6-10]. Likewise, persons with genetic mutations in the
interferon-gamma or interleukin-12 cytokine pathways
can present with widely disseminated TB disease [11,12].
At the other end of the spectrum, patients with a
recovering immune system, such as persons with HIV
who are initiating antiretroviral therapy or persons stop-
ping anti-tumor necrosis factor therapy, can have an
overexuberant immune response to TB infection charac-
terized by extensive cavitary lung lesions and necrotic
lymph nodes [13].
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While TST reactivity is recognized to be an indicator
of TB infection following exposure to persons with TB
disease and has been widely studied in the context of la-
tent TB infection [14], we are not aware of any large
studies that describe the pattern of TST results among
persons with different clinical presentations of active TB
disease. Understanding the association between the TST
and clinical manifestations of TB disease may provide
insight into the host-pathogen relationship and how fac-
tors such as HIV infection may influence that relation-
ship. We analyzed national surveillance data from the
United States to explore whether the TST result corre-
lates with differences in the clinical presentation of
active TB among a large cohort of persons with
bacteriologically-confirmed TB disease.
Methods
We analyzed reports of persons with culture-confirmed
TB in the National Tuberculosis Surveillance System of
the Centers for Disease Control and Prevention (CDC)
during January 1, 1993 through December 31, 2010. The
analysis included persons with a documented TST re-
sult, anatomical site of disease, HIV status, and birth-
place (US- or foreign-born). Cases of pulmonary TB
without a chest radiograph result were excluded to allow
for evaluation of the association between radiograph
findings and TST result. Reports from California were
also excluded because HIV status was not routinely
reported from that jurisdiction prior to 2011 [15].
Based on CDC guidelines for the classification of TST
reactions, the TST result was divided into categories of
0–4 mm, 5–9 mm, 10–14 mm, and ≥ 15 mm [14]. A
TST result of 0–4 mm was considered negative and a
result ≥ 5 mm was considered positive. Pearson’s chi-
square statistic was used to assess differences in the
distribution of TST results for sociodemographic and
clinical characteristics. Clinical presentation of disease
was defined as one of the following mutually exclusive
categories: miliary disease, combined pulmonary and
extrapulmonary disease, extrapulmonary only disease,
and pulmonary only disease which was further divided
into non-cavitary pulmonary disease and cavitary pul-
monary disease. A designation of miliary disease was
based on either clinical impression or a miliary radio-
graphic pattern on either chest radiograph or CT scan.
Multinomial logistic regression was used to examine
the association between TST result category and clinical
presentation of disease category and to calculate odds
ratios and 95% confidence intervals. Non-cavitary pul-
monary disease was the largest clinical presentation cat-
egory and was used as the referent outcome category. A
TST of 0–4 mm (negative) was used as the referent cat-
egory for TST result. Persons with non-cavitary pulmon-
ary disease with a TST of 0–4 mm served as the
comparison group to calculate odds ratios for each of
the respective clinical presentation/TST result category
combinations (e.g., cavitary pulmonary disease with
TST ≥ 15 mm or miliary disease with TST 10–14 mm
were all compared to non-cavitary pulmonary disease
with a TST of 0–4 mm). We examined the following
covariates for effect modification or confounding: sex,
age, race and ethnicity (self-designated), HIV status,
birthplace, incarceration at the time of diagnosis, home-
lessness in the 12 months prior to diagnosis, and exces-
sive alcohol or illicit drug use in the 12 months prior to
diagnosis. Finally, we conducted an additional analysis
restricted to persons with exclusively pulmonary disease
who had a documented sputum smear result at baseline.
Multivariate logistic regression was used to calculate
odds ratios and 95% confidence intervals to quantify the
odds of having a positive sputum smear (vs. negative) re-
sult for acid-fast bacilli (AFB) for each TST category
(TST 0–4 mm referent).
As data were collected as part of routine TB surveil-
lance by the CDC, this analysis was not considered re-
search involving human subjects, and institutional
review board approval was not required.
Results
Distribution of TST results
During 1993 through 2010, there were 308,740 cases of
tuberculosis reported in the United States, of which
244,413 (79%) were culture-confirmed (Figure 1). Of
these cases, 125,026 (51%) had a TST result reported
(see Additional file 1, in the online supplement for a
comparison of sociodemographic and clinical character-
istics of persons with and without a TST result reported,
which shows significant differences between persons
with and without TST results for all characteristics) of
which 64,238 persons with culture-confirmed TB were
eligible for inclusion in the analysis. Among these per-
sons, 15.9% had a TST of 0–4 mm (negative), 2.6% had a
TST of 5–9 mm, 21.9% had a TST of 10–14 mm, and
59.7% had a TST ≥ 15 mm (Table 1). The proportion of
persons with a negative TST was greater in those with
age > 45 years, male sex, non-Hispanic white race/ethni-
city, who were born in the US, infected with HIV, or
who had a positive sputum smear result for AFB at
baseline. The distribution of TST results was signifi-
cantly different among persons with and without HIV:
12.5% of persons without HIV had a negative TST while
38.2% of persons with HIV had a negative TST. Persons
with miliary disease and combined pulmonary and
extrapulmonary disease also had high rates of TST
negativity, 36.7% and 22.9%, respectively, whereas per-
sons with extrapulmonary only, or cavitary pulmonary
disease had lower rates of a negative TST with 13.8%
and 13.0%, respectively. The distributions of TST
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results within each sociodemographic and clinical
characteristic comparison were statistically significant
with a P-value < 0.001.
TST result and clinical category of disease
In general, we found that persons with a TST ≥ 15 mm
were less likely to have miliary or combined pulmonary
and extrapulmonary disease, but more likely to have
cavitary pulmonary disease relative to non-cavitary pul-
monary disease (Table 2 and Figure 2). However, we
found statistical interaction between TST result and the
covariates of age, sex, HIV status, and birthplace. Be-
cause of an a priori interest in the potential for HIV sta-
tus and birthplace to influence immune system priming
and immune status, we chose to stratify the analysis by
HIV status and birthplace (Table 2 and Figure 2). Age
and sex were retained in the subsequent regression
models but in the interest of presenting a focused ana-
lysis we did not stratify on them. The other covariates
did not appreciably impact the regression models.
Across all strata, persons with a TST ≥ 15 mm had sig-
nificantly decreased odds of miliary disease relative to
non-cavitary pulmonary disease. (Non-cavitary pulmon-
ary disease will continue to be the referent group for all
subsequent comparisons.) The inverse relationship be-
tween a positive TST and miliary disease was strongest
among persons without HIV for whom those with a
TST ≥ 15 mm had 59–81% lower odds of having miliary
disease (US-born adjusted odds ratio [aOR] 0.41 [95%
confidence interval [CI] 0.32, 0.53]; foreign-born aOR
0.19 [95% CI 0.15, 0.25]) (Table 2 and Figure 2). Persons
with HIV who had a TST ≥ 15 mm had 41–50% lower
odds of having miliary disease (US-born aOR 0.50 [95%
CI 0.37, 0.68]; foreign-born aOR 0.59 [95% CI 0.40,
0.86]). Persons with a TST of 5–9 mm or 10–14 mm
also had decreased odds of miliary disease; however, the
associations were not consistently statistically significant.
Persons with a positive TST were also less likely to
have combined pulmonary and extrapulmonary disease.
However, the associations were not as strong as those
seen with miliary disease (Table 2 and Figure 2). Persons
without HIV who had a TST ≥ 15 mm were signifi-
cantly less likely to have combined pulmonary and
extrapulmonary disease and the strength of association
was stronger among foreign-born persons than US-
born persons (foreign-born aOR 0.56 [95% CI 0.48,
0.67]; US-born aOR 0.80 [95% CI 0.70, 0.93]). Among
persons with HIV, the association between TST result
and having combined pulmonary and extrapulmonary
disease was significant for foreign-born persons with a
TST of ≥ 15 mm (aOR 0.65 [95% CI 0.50, 0.84]) but not
for US-born persons (aOR 0.86 [95% CI 0.72, 1.03]).
308,740 Reported TB cases 1993–2010
64,327 not culture -confirmed
244,413 Culture-confirmed cases
119,387 TST result unknown
125,026 Cases with a TST result 
42 disease site unknown
3,665 CXR unknown(for pulmonary only)*
121,319 Cases with a documented disease site and CXR result (for pulmonary only)
24,321 from California
96,998 Cases from non-California jurisdictions
32,635 HIV status unknown
125 birthplace unknown
64,238 Cases with documented HIV status and birthplace
1,151 Miliary 4,405 Pulmonary & extrapulmonary 9,169 Extrapulmonary only    49,513 Pulmonary only
30,903 Non-cavitary pulmonary 18,610 Cavitary pulmonary
Figure 1 Selection of United States TB cases reported to CDC during 1993 through 2010 for inclusion in the analysis of the
relationship between tuberculin skin test (TST) results and clinical presentation. *CXR = chest radiograph.
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US-born persons without HIV and all persons with HIV
who had a TST ≥ 15 mm were significantly more likely to
have cavitary pulmonary disease. The strength of associ-
ation was greatest for foreign-born persons with HIV where
those with a TST of ≥ 15 mm had an aOR of 2.20 (95% CI
1.60, 3.02) for having cavitary pulmonary disease. In con-
trast, foreign-born persons without HIV who had a positive
TST were less likely to have cavitary pulmonary disease
(aOR 0.81 [95% CI 0.73–0.90] for TST ≥ 15 mm).
With regard to extrapulmonary only disease, there
were no consistent differences between the odds of
extrapulmonary disease and non-cavitary pulmonary
disease by TST result.
TST result and sputum smear positivity
Among persons with exclusively pulmonary disease, 50%
of those with non-cavitary disease and 83% of those with
cavitary disease had a positive sputum smear (Table 3).
Table 1 Tuberculin skin test (TST) result and characteristics of selected culture-confirmed TB cases reported in the
United States, 1993–2010 (N = 64,238)
TST 0–4 mm TST 5–9 mm TST 10–14 mm TST ≥ 15 mm P-value*
(n,%) (n,%) (n,%) (n,%)
Total 10,181 (15.9) 1,635 (2.6) 14,049 (21.9) 38,737 (59.7)
Age
0–4 52 (9.3) 30 (5.4) 169 (30.2) 308 (55.1) < 0.001
5–14 29 (5.7) 9 (1.8) 102 (20.0) 369 (72.5)
15–24 658 (7.6) 213 (2.5) 1,891 (21.8) 5,923 (68.2)
25–44 4,288 (15.0) 656 (2.3) 6,235 (21.8) 17,450 (61.0)
45–64 3,310 (18.0) 496 (2.7) 4,086 (22.2) 10,486 (57.1)
65+ 1,839 (24.6) 230 (3.1) 1,563 (20.9) 3,831 (51.3)
Sex
Male 7,445 (17.5) 1,149 (2.7) 9,483 (22.3) 24,441 (57.5) < 0.001
Female 2,731 (12.6) 485 (2.2) 4,563 (21.0) 13,916 (64.1)
Race/ethnicity
Hispanic 2,203 (14.7) 404 (2.7) 3,500 (23.4) 8,856 (59.2) < 0.001
American Indian 114 (14.0) 20 (2.5) 133 (16.3) 550 (67.3)
Asian 673 (6.9) 255 (2.6) 2,153 (22.2) 6,630 (68.3)
Black 4,164 (16.7) 529 (2.1) 5,162 (20.7) 15,113 (60.5)
Native Hawaiian 46 (6.8) 18 (2.7) 158 (23.3) 455 (67.2)
White 2,944 (23.1) 400 (3.1) 2,870 (22.5) 6,546 (51.3)
Birthplace
US-born 6,853 (19.8) 881 (2.5) 7,438 (21.4) 19,530 (56.3) < 0.001
Foreign-born 3,328 (11.3) 754 (2.6) 6,611 (22.4) 18,843 (63.8)
HIV status
Negative 6,997 (12.5) 1,409 (2.5) 12,358 (22.1) 35,131 (62.9) < 0.001
Positive 3,184 (38.2) 226 (2.7) 1,691 (20.3) 3,242 (38.9)
Clinical presentation of disease
Miliary 422 (36.7) 43 (3.7) 221 (19.2) 465 (40.4) < 0.001
Pulmonary/extrapulmonary 1,010 (22.9) 120 (2.7) 869 (19.7) 2,406 (54.6)
Extrapulmonary 1,261 (13.8) 207 (2.3) 1,870 (20.4) 5,831 (63.6)
Non-cavitary pulmonary 5,061 (16.4) 769 (2.5) 6,805 (22.0) 18,268 (59.1)
Cavitary pulmonary 2,427 (13.0) 496 (2.7) 4,284 (23.0) 11,403 (61.3)
Sputum smear
Negative 3,350 (13.7) 570 (2.3) 5,138 (21.0) 15,384 (62.9) < 0.001
Positive 5,111 (16.4) 854 (2.7) 7,058 (22.6) 18,147 (58.2)
*Pearson’s chi-square test.
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For persons with non-cavitary pulmonary disease, the
odds of having a positive sputum smear result for AFB
were significantly decreased among those with a TST ≥
10 mm. Foreign-born persons with HIV who had a
TST ≥ 15 mm had half the odds of having a positive spu-
tum smear when compared to those with a negative TST
(aOR 0.50 [95% CI 0.39–0.65]). However, among persons
with cavitary pulmonary disease, TST had no consistent
association with sputum smear status.
Discussion
In this analysis of TB cases in the United States, 15.9%
of persons with culture-confirmed TB had a negative
TST result, and clinical presentation of disease differed
by TST result. Overall, persons with a negative TST
result were significantly more likely to have miliary
or combined pulmonary and extrapulmonary disease,
which is consistent with reports from smaller cohorts
[1,16,17]. At the same time, persons with a positive TST
were typically more likely to have cavitary pulmonary
disease as compared to non-cavitary pulmonary disease.
Table 2 Multinomial associations between clinical presentation of disease and tuberculin skin test (TST) result
stratified by HIV status and birthplace and adjusted for age and sex among selected culture confirmed TB cases
reported in the United States, 1993–2010 (N = 64,238)
Miliary disease Pulmonary & Extrapulmonary disease Extrapulmonary only disease Cavitary pulmonary disease
aOR* 95% CI* aOR 95% CI aOR 95% CI aOR 95% CI
HIV+/US
0–4 mm Ref Ref Ref
5–9 mm 0.96 0.47, 1.95 0.72 0.42, 1.22 1.29 0.81, 2.06 1.11 0.64, 1.94
10–14 mm 0.72 0.51, 1.01 0.81 0.65, 1.01 1.23 1.00, 1.53 1.36 1.07, 1.72
≥ 15 mm 0.50 0.37, 0.68 0.86 0.72, 1.03 1.09 0.91, 1.31 1.56 1.29, 1.90
HIV+/FB
0–4 mm Ref Ref Ref Ref
5–9 mm 0.18 0.02, 1.29 0.93 0.49, 1.79 1.01 0.53, 1.94 1.68 0.75, 3.75
10–14 mm 0.66 0.42, 1.04 0.80 0.60, 1.08 0.96 0.71, 1.28 1.85 1.27, 2.69
≥ 15 mm 0.59 0.40, 0.86 0.65 0.50, 0.84 1.16 0.92, 1.47 2.20 1.60, 3.02
HIV-/US
0–4 mm Ref Ref Ref Ref
5–9 mm 0.77 0.43, 1.38 1.09 0.78, 1.52 1.05 0.79, 1.39 1.32 1.11, 1.56
10–14 mm 0.49 0.37, 0.66 0.77 0.64, 0.91 1.05 0.92, 1.20 1.09 1.00, 1.18
≥ 15 mm 0.41 0.32, 0.53 0.80 0.70, 0.93 1.11 0.99, 1.24 1.11 1.03, 1.20
HIV-/FB
0–4 mm Ref Ref Ref Ref
5–9 mm 0.56 0.34, 0.93 0.61 0.43, 0.86 0.82 0.63, 1.06 0.84 0.69, 1.04
10–14 mm 0.22 0.16, 0.30 0.51 0.42, 0.62 0.85 0.74, 0.99 0.92 0.82, 1.03
≥ 15 mm 0.19 0.15, 0.25 0.56 0.48, 0.67 1.03 0.90, 1.17 0.81 0.73, 0.90
Non-cavitary pulmonary disease, with the largest number of cases, is the referent clinical category and 0–4 mm (negative) is the referent TST category for
all comparisons.
*aOR adjusted odds ratio, 95% CI 95% Confidence Interval.
Note: Numbers in bold represent significant 95% confidence intervals.
Figure 2 Association between TST result and clinical presentation
of disease relative to a TST of 0–4 mm and relative to non-cavitary
pulmonary disease, stratified by HIV status and birthplace and
adjusted for age and sex (N = 64,238). The log of the adjusted odds
ratio and their 95% confidence intervals are presented.
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A similar relationship has been seen in a rabbit model of
aerosolized TB infection whereby more cavities were
present in rabbits with strong tuberculin reactions [18].
Importantly, the associations between TST result and
clinical presentation of disease were substantially im-
pacted by HIV status and birthplace.
We found that half of persons with non-cavitary pul-
monary disease had positive sputum smear results, and
this smear positivity was significantly associated with
having a negative TST. This association between sputum
smear result and TST result was not seen in persons
with cavitary pulmonary disease. Our findings support
the notion that there may be several mechanisms for the
buildup of sufficient bacteria to be visualized by smear
microscopy, and smear positive disease in the absence of
cavities may be associated with some aspect of immune
function that is assayed by the TST [19]. Additionally,
several recent studies suggest that Mycobacterium tuber-
culosis (M. tuberculosis) benefits from a more active im-
mune response and postulate that direct engagement of
M. tuberculosis with the human immune system favors
cavity formation thereby increasing the likelihood of
subsequent aerosol transmission [20-23]. Taken together
with our results, this suggests a complex interaction be-
tween M. tuberculosis and the host immune system that
results in different disease manifestations and potential
for transmission.
Our finding that HIV status and birthplace impacted
the association between TST result and clinical presen-
tation of disease is noteworthy. Associations between
TST result and clinical presentation were generally con-
sistent across all strata with the exception of cavitary
pulmonary disease. Persons with HIV and US-born
persons without HIV who had a TST ≥ 15 mm were
Table 3 Association between TST result and sputum smear result for AFB among persons with culture-confirmed
pulmonary TB, stratified by HIV status and birthplace and adjusted for age and sex (N = 46,680)
Non-cavitary pulmonary disease Cavitary pulmonary disease
Total Smear-positive (%) aOR* 95% CI* Total Smear-positive (%) aOR 95% CI
HIV+/US
0–4 mm 1,073 651 (61) Ref 183 135 (74) Ref
5–9 mm 79 44 (56) 0.78 0.49, 1.24 16 14 (88) 2.66 0.58, 12.27
10–14 mm 603 317 (53) 0.72 0.59, 0.88 139 117 (84) 1.90 1.08, 3.35
≥ 15 mm 1,182 545 (46) 0.56 0.47, 0.66 320 245 (77) 1.15 0.75, 1.75
Sub-total 2,937 1,557 (53) 658 511 (78)
HIV+/FB
0–4 mm 522 325 (62) Ref 62 48 (77) Ref
5–9 mm 36 24 (67) 1.20 0.59, 2.47 7 4 (57) 0.37 0.07, 1.86
10–14 mm 267 140 (52) 0.67 0.50, 0.91 61 37 (61) 0.45 0.20, 1.00
≥ 15 mm 483 217 (45) 0.50 0.39, 0.65 130 102 (78) 1.03 0.49, 2.16
Sub-total 1,308 706 (54) 260 191 (73)
HIV-/US
0–4 mm 2,051 1,195 (58) Ref 1,430 1,232 (86) Ref
5–9 mm 285 159 (56) 0.89 0.69, 1.14 273 236 (86) 0.99 0.68, 1.44
10–14 mm 2,759 1,504 (55) 0.84 0.74, 0.94 2,137 1,795 (84) 0.78 0.64, 0.95
≥ 15 mm 7,576 3,745 (49) 0.69 0.62, 0.76 5,960 5,027 (84) 0.80 0.68, 0.95
Sub-total 12,671 6,603 (52) 9,800 8,290 (85)
HIV-/FB
0–4 mm 831 468 (56) Ref 600 482 (80) Ref
5–9 mm 314 159 (51) 0.78 0.60, 1.02 180 150 (83) 1.23 0.79, 1.91
10–14 mm 2,702 1,338 (50) 0.74 0.63, 0.87 1,790 1,466 (82) 1.10 0.87, 1.39
≥ 15 mm 7,992 3,626 (45) 0.62 0.54, 0.72 4,637 3,754 (81) 1.03 0.83, 1.28
Sub-total 11,839 5,591 (47) 7,207 5,852 (81)
Total 28,755 14,457 (50) 19,925 14,844 (83)
Probability modeled is of sputum AFB smear positivity.
*aOR adjusted odds ratio, 95% CI 95% Confidence Interval.
Note: Numbers in bold represent significant 95% confidence intervals.
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significantly more likely to have cavitary pulmonary dis-
ease while foreign-born persons without HIV who had a
TST ≥ 15 mm were significantly less likely to have cavi-
tary pulmonary disease.
The basis of these differences according to birthplace
is not known; however, US- and foreign-born persons
with TB in the US differ in several notable respects. One
difference in these populations is in the likelihood of
previous exposure to M. tuberculosis complex. Most
foreign-born cases of TB in the US are among persons
from countries with high rates of TB and thus potential
for repeated exposure in their country of origin [24,25].
Additionally, BCG vaccination as a child is virtually uni-
versal among immigrants to the US from medium and
high TB burden countries. Thus, foreign-born persons
who develop TB in the US are substantially more likely
to have had prior exposure to mycobacteria (TB and/or
BCG) with resultant sensitization of their immune
system and the potential for pre-existing immune
function directed against mycobacteria. This immune
priming may serve to limit more disseminated forms of
TB disease (i.e., miliary and combined pulmonary and
extrapulmonary), in a manner potentially analogous to
BCG vaccination where vaccinated children have de-
creased incidence of disseminated disease.
Another potential difference between US- and foreign-
born persons may be the timing of disease relative to in-
fection. Disease among US-born persons is more often
associated with recent transmission whereas TB among
foreign-born persons in the US is thought to be primar-
ily due to reactivation of latent TB [24,26,27]. Hence,
cavitation may represent a vigorous, but locally dam-
aging immune response more commonly associated with
recent infection. The lower risk of cavitation seen among
foreign-born persons without HIV who had a positive
TST may represent a “survivor effect” related to different
disease manifestations in the setting of reactivation dis-
ease. It is also possible that US- and foreign-born per-
sons have differences in their likelihood of undergoing
TB screening or different social or nutritional factors
that impact both their immune response and their pres-
entation of disease [28,29].
This analysis utilized cross-sectional data and so we
could not determine the relative timing of clinical disease
presentation and TST result. Prospective studies are
needed to determine whether the immune response repre-
sented by the TST is a driver of clinical disease presenta-
tion or a consequence of infection where, for example,
greater presence of mycobacteria may trigger a larger TST
response. Although numerous reviews cite disseminated
infection as a potential cause of a negative TST in the set-
ting of active disease, it is also possible that disseminated
infection occurs as a result of a diminished or impaired
host immune response as assayed by the TST [1,3,30].
By limiting our analysis to persons with a docu-
mented TST result, we excluded nearly half of the
TB cases reported in the United States during the
study period. Statistically significant differences were
found between the included and excluded popula-
tions for all sociodemographic and clinical variables.
Therefore, there is a possibility that the population
studied was not representative of the entire US sur-
veillance cohort. Nevertheless, we were still able to
include a very large cohort of persons with culture-
confirmed TB. We also limited our analysis to per-
sons with a known HIV status because we found
that the relationship between TST result and clinical
presentation varied by HIV status. Similarly, data
from California, which accounts for approximately
20% of TB cases in the United States, were excluded
because HIV results were not routinely reported to
CDC. However, results of a sensitivity analysis in-
cluding cases reported from California were not ap-
preciably different (data not shown).
Conclusions
Overall, this analysis provides recent population-level
data about the relationship between TST result, a
marker of host immune response, and the clinical
presentation of active TB disease. Our findings
suggest that the significance of the TST result may
extend beyond its traditional role as a marker of in-
fection and may be relevant to the pathophysiology
and presentation of active disease, even among
persons without overt immune dysfunction. The dif-
ferences in site of disease by TST result may indi-
cate that the TST could be a useful adjunct for
identifying patients with different underlying im-
mune system susceptibility to and interaction with
M. tuberculosis. A better understanding of these
differences may provide insight into differential re-
sponses to vaccine candidates or TB treatment. Our
finding that persons with a positive TST result were
less likely to have disseminated disease may parallel
the effect of BCG immunization which usually re-
sults in transient TST positivity and decreased risk
of disseminated disease in children [31]. Future vac-
cine trials may want to consider including both TST
result and clinical presentation of TB disease in their
study outcomes since immunization may impact the
likelihood of cavity formation or of disseminated dis-
ease, both of which would have implications for TB
transmission and mortality. Broader incorporation of
tuberculin skin testing in TB trials and prospective
studies may prove informative as part of the ongoing
effort to better understand the relationship between
the immune system and Mycobacterium tuberculosis.
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